Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Mueller-Brand

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
European Journal of Nuclear Medicine|July 1, 1997
Brain glucose utilization in systemic lupus erythematosus with neuropsychiatric symptoms: a controlled positron emission tomography studyA Otte, S M Weiner, H H Peter, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 27, 2002
Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot studyT Schumacher, S Hofer, K Eichhorn, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 8, 2013
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumoursL Bodei, J Mueller-Brand, R P Baum, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
European Journal of Nuclear Medicine|July 1, 1997
Brain glucose utilization in systemic lupus erythematosus with neuropsychiatric symptoms: a controlled positron emission tomography studyA Otte, S M Weiner, H H Peter, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 27, 2002
Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot studyT Schumacher, S Hofer, K Eichhorn, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 8, 2013
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumoursL Bodei, J Mueller-Brand, R P Baum, et al.
Pageof 4